Oligonucleotide Synthesis Market Projection: Growth to $18.67 Billion by 2028 with Significant Trends, Market Segments, and Competitive Analysis

The new report published by The Business Research Company, titled Oligonucleotide Synthesis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the oligonucleotide synthesis market size has grown rapidly in recent years. It will grow from $8.85 billion in 2023 to $10.27 billion in 2024 at a compound annual growth rate (CAGR) of 16.0%. The oligonucleotide synthesis market size is expected to see rapid growth in the next few years. It will grow to $18.67 billion in 2028 at a compound annual growth rate (CAGR) of 16.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=12176&type=smp

The Oligonucleotide Synthesis Market Set To Expand With The Rising Prevalence Of Chronic Diseases
The rising prevalence of chronic diseases is expected to propel the growth of the oligonucleotide synthesis market going forward. Chronic diseases refer to conditions that last one year or longer and require continuous medical attention, which may worsen over time. Oligonucleotides, via various mechanisms, act on gene expression that causes chronic diseases. They can target mRNA, pre-mRNA, or non-coding RNA to modulate splicing events, induce degradation, or interfere with protein translation. For instance, in January 2022, according to the International Diabetes Federation, a Belgium-based organization of national diabetes associations, the global diabetes prevalence in 20-79-year-olds was 536.6 million in 2021 and is expected to increase by 12.2% in 2045. Furthermore, in September 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the rising prevalence of chronic and rare diseases is driving the growth of the oligonucleotide synthesis market.

Companies Introducing Innovative Solutions To Pioneer Innovation In The Oligonucleotide Synthesis Market
Product innovation is the key trend gaining popularity in the oligonucleotide synthesis market. Major companies operating in the oligonucleotide synthesis market are developing innovative products to sustain their position in the market. For instance, in July 2021, DNA Script, a France-based DNA synthesis company, launched Syntax, a benchtop DNA printer designed for molecular biology and genomics applications. The printer enables the on-site synthesis of DNA oligonucleotides (oligos) for genomics workflow. Syntax, powered by the enzymatic DNA synthesis (EDS) technology of DNA Script, is the company's first tabletop nucleic acid printer. The Syntax system has a desktop DNA printer, consumables and reagent kits, and management software. The Syntax takes less than 15 minutes to set up and can synthesize 20 meters in as little as six hours and as many as 60 meters in as little as 13 hours. The printer then purifies, quantifies, and normalizes the oligos when synthesis is finished so they can be used in the following stage of the research procedure.

The oligonucleotide synthesis market covered in this report is segmented -

1) By Type: Custom Oligos, Predesigned Oligos
2) By Product Type: Oligonucleotides, Reagents, Equipment, Services, Purification, Modification
3) By Application: Therapeutic Applications, Research Applications, Diagnostic Applications

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=12176&type=discount

Major companies operating in the oligonucleotide synthesis market report are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE HealthCare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Nitto Denko Avecia Inc., Alnylam Pharmaceuticals Inc., Maravai Life Sciences, LGC Limited, Ionis Pharmaceuticals Inc., GenScript Inc., Ajinomoto Bio-Pharma Services, Sarepta Therapeutics Inc., Integrated DNA Technologies Inc., Twist Bioscience Corporation, Eurogentec SA, Kaneka Eurogentec S.A., Biocomma Limited, Bio-Synthesis Inc., TriLink BioTechnologies Incorporated, Generi Biotech s.r.o., ATDBio Ltd., BioAutomation Corporation, Biolegio B.V., Dharmacon Research Inc.

Contents of the report:
1. Executive Summary
2. Oligonucleotide Synthesis Market Report Structure
3. Oligonucleotide Synthesis Market Trends And Strategies
4. Oligonucleotide Synthesis Market - Macro Economic Scenario
5. Oligonucleotide Synthesis Market Size And Growth
…..
27. Oligonucleotide Synthesis Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/oligonucleotide-synthesis-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.